Press centre

Latest

26 Mar 2021

Thailand Activates First Site in Global Phase 3 Clinical Study of Zoliflodacin as a New Gonorrhoea Treatment

GARDP and Entasis Therapeutics announced today the activation of the first site in Thailand as part of a global phase 3 clinical study of zoliflodacin for the treatment of gonorrhoea.

15 Apr 2021

GARDP and French Ministry for Europe and Foreign Affairs Sign Declaration of Intent to Tackle Antibiotic Resistance

10 Mar 2021

Swiss Government Grants Privileged Status to GARDP Foundation

12 Feb 2021

GARDP Welcomes Additional Funding from UK to Develop New Treatment for Gonorrhoea

27 Jan 2021

GARDP and Entasis Therapeutics Announce South Africa Site Activation in Global Phase 3 Study of Zoliflodacin as a New Gonorrhoea Treatment

20 Jan 2021

GARDP and BSAC Sign MOU to Collaborate on Antibiotic Resistance Education, Policy and Advocacy

17 Dec 2020

GARDP, Dr. Reddy’s and Aurigene Pharmaceutical Services Limited Sign MOU for Antibiotic Access Through Collaborative Model

Media contacts

For media inquiries, please contact the GARDP Communications Department:

Phone: +41 22 555 19 90 | Email: communications@gardp.org

Cookie Policy

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.